Recent advances in multidisciplinary approach for rectal cancer

Eiji Oki, Kouji Andou, Yuta Kasagi, Yoko Zaitsu, Masahiko Sugiyama, Yuichiro Nakashima, Hideto Sonoda, Kippei Ohgaki, Hiroshi Saeki, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿評論記事

2 引用 (Scopus)

抄録

Surgery is a major treatment option for rectal cancer, and total mesorectal excision has been demonstrated to be advantageous in terms of oncological outcome and thus has been the standard surgical approach. Radiotherapy before or after radical surgery is the optimal treatment to control local recurrence of advanced rectal cancer. To date, in many countries, the combination of neoadjuvant concurrent chemotherapy and radiotherapy is considered the standard therapy. A more recent interest in neoadjuvant therapy has been the use of oxaliplatin or targeted agents for neoadjuvant chemoradiotherapy. However, despite many trials of oxaliplatin and targeted agents, 5-FU-based concurrent chemoradiotherapy has remained the only standard treatment option. Postoperative adjuvant chemotherapy with neoadjuvant chemoradiotherapy or induction chemotherapy with neoadjuvant chemoradiotherapy may further improve patient survival, as some clinical studies recently indicated. In Japan, neoadjuvant therapy is not the standard treatment method, because surgery with lateral lymph node dissection is usually performed and this type of surgery may reduce recurrence rate as does radiation therapy. The phase III study to evaluate the oncological effect of the Japanese standard operation (mesorectal excision, ME) with lateral lymph node dissection in comparison with ME alone for clinical stage II and III lower rectal cancer is currently ongoing.

元の言語英語
ページ(範囲)641-649
ページ数9
ジャーナルInternational Journal of Clinical Oncology
20
発行部数4
DOI
出版物ステータス出版済み - 8 8 2015

Fingerprint

Rectal Neoplasms
oxaliplatin
Chemoradiotherapy
Neoadjuvant Therapy
Radiotherapy
Lymph Node Excision
Therapeutics
Recurrence
Induction Chemotherapy
Adjuvant Chemotherapy
Fluorouracil
Japan
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

これを引用

Recent advances in multidisciplinary approach for rectal cancer. / Oki, Eiji; Andou, Kouji; Kasagi, Yuta; Zaitsu, Yoko; Sugiyama, Masahiko; Nakashima, Yuichiro; Sonoda, Hideto; Ohgaki, Kippei; Saeki, Hiroshi; Maehara, Yoshihiko.

:: International Journal of Clinical Oncology, 巻 20, 番号 4, 08.08.2015, p. 641-649.

研究成果: ジャーナルへの寄稿評論記事

Oki, E, Andou, K, Kasagi, Y, Zaitsu, Y, Sugiyama, M, Nakashima, Y, Sonoda, H, Ohgaki, K, Saeki, H & Maehara, Y 2015, 'Recent advances in multidisciplinary approach for rectal cancer', International Journal of Clinical Oncology, 巻. 20, 番号 4, pp. 641-649. https://doi.org/10.1007/s10147-015-0858-8
Oki, Eiji ; Andou, Kouji ; Kasagi, Yuta ; Zaitsu, Yoko ; Sugiyama, Masahiko ; Nakashima, Yuichiro ; Sonoda, Hideto ; Ohgaki, Kippei ; Saeki, Hiroshi ; Maehara, Yoshihiko. / Recent advances in multidisciplinary approach for rectal cancer. :: International Journal of Clinical Oncology. 2015 ; 巻 20, 番号 4. pp. 641-649.
@article{3629661e04f04cbe94bf3652f75bc5d5,
title = "Recent advances in multidisciplinary approach for rectal cancer",
abstract = "Surgery is a major treatment option for rectal cancer, and total mesorectal excision has been demonstrated to be advantageous in terms of oncological outcome and thus has been the standard surgical approach. Radiotherapy before or after radical surgery is the optimal treatment to control local recurrence of advanced rectal cancer. To date, in many countries, the combination of neoadjuvant concurrent chemotherapy and radiotherapy is considered the standard therapy. A more recent interest in neoadjuvant therapy has been the use of oxaliplatin or targeted agents for neoadjuvant chemoradiotherapy. However, despite many trials of oxaliplatin and targeted agents, 5-FU-based concurrent chemoradiotherapy has remained the only standard treatment option. Postoperative adjuvant chemotherapy with neoadjuvant chemoradiotherapy or induction chemotherapy with neoadjuvant chemoradiotherapy may further improve patient survival, as some clinical studies recently indicated. In Japan, neoadjuvant therapy is not the standard treatment method, because surgery with lateral lymph node dissection is usually performed and this type of surgery may reduce recurrence rate as does radiation therapy. The phase III study to evaluate the oncological effect of the Japanese standard operation (mesorectal excision, ME) with lateral lymph node dissection in comparison with ME alone for clinical stage II and III lower rectal cancer is currently ongoing.",
author = "Eiji Oki and Kouji Andou and Yuta Kasagi and Yoko Zaitsu and Masahiko Sugiyama and Yuichiro Nakashima and Hideto Sonoda and Kippei Ohgaki and Hiroshi Saeki and Yoshihiko Maehara",
year = "2015",
month = "8",
day = "8",
doi = "10.1007/s10147-015-0858-8",
language = "English",
volume = "20",
pages = "641--649",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Recent advances in multidisciplinary approach for rectal cancer

AU - Oki, Eiji

AU - Andou, Kouji

AU - Kasagi, Yuta

AU - Zaitsu, Yoko

AU - Sugiyama, Masahiko

AU - Nakashima, Yuichiro

AU - Sonoda, Hideto

AU - Ohgaki, Kippei

AU - Saeki, Hiroshi

AU - Maehara, Yoshihiko

PY - 2015/8/8

Y1 - 2015/8/8

N2 - Surgery is a major treatment option for rectal cancer, and total mesorectal excision has been demonstrated to be advantageous in terms of oncological outcome and thus has been the standard surgical approach. Radiotherapy before or after radical surgery is the optimal treatment to control local recurrence of advanced rectal cancer. To date, in many countries, the combination of neoadjuvant concurrent chemotherapy and radiotherapy is considered the standard therapy. A more recent interest in neoadjuvant therapy has been the use of oxaliplatin or targeted agents for neoadjuvant chemoradiotherapy. However, despite many trials of oxaliplatin and targeted agents, 5-FU-based concurrent chemoradiotherapy has remained the only standard treatment option. Postoperative adjuvant chemotherapy with neoadjuvant chemoradiotherapy or induction chemotherapy with neoadjuvant chemoradiotherapy may further improve patient survival, as some clinical studies recently indicated. In Japan, neoadjuvant therapy is not the standard treatment method, because surgery with lateral lymph node dissection is usually performed and this type of surgery may reduce recurrence rate as does radiation therapy. The phase III study to evaluate the oncological effect of the Japanese standard operation (mesorectal excision, ME) with lateral lymph node dissection in comparison with ME alone for clinical stage II and III lower rectal cancer is currently ongoing.

AB - Surgery is a major treatment option for rectal cancer, and total mesorectal excision has been demonstrated to be advantageous in terms of oncological outcome and thus has been the standard surgical approach. Radiotherapy before or after radical surgery is the optimal treatment to control local recurrence of advanced rectal cancer. To date, in many countries, the combination of neoadjuvant concurrent chemotherapy and radiotherapy is considered the standard therapy. A more recent interest in neoadjuvant therapy has been the use of oxaliplatin or targeted agents for neoadjuvant chemoradiotherapy. However, despite many trials of oxaliplatin and targeted agents, 5-FU-based concurrent chemoradiotherapy has remained the only standard treatment option. Postoperative adjuvant chemotherapy with neoadjuvant chemoradiotherapy or induction chemotherapy with neoadjuvant chemoradiotherapy may further improve patient survival, as some clinical studies recently indicated. In Japan, neoadjuvant therapy is not the standard treatment method, because surgery with lateral lymph node dissection is usually performed and this type of surgery may reduce recurrence rate as does radiation therapy. The phase III study to evaluate the oncological effect of the Japanese standard operation (mesorectal excision, ME) with lateral lymph node dissection in comparison with ME alone for clinical stage II and III lower rectal cancer is currently ongoing.

UR - http://www.scopus.com/inward/record.url?scp=84938748467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938748467&partnerID=8YFLogxK

U2 - 10.1007/s10147-015-0858-8

DO - 10.1007/s10147-015-0858-8

M3 - Review article

C2 - 26100273

AN - SCOPUS:84938748467

VL - 20

SP - 641

EP - 649

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -